Asian Tech Press (Apr. 26) -- Sinopharm's COVID-19 vaccine candidate against Omicron variant got approval for clinical trials in China.

China National Biotec Group Co., Ltd. (CNBG), a subsidiary of Chinese state-owned drugmaker Sinopharm Group Co. Ltd., announced Tuesday its Omicron-specific COVID-19 vaccine candidate has received approval from the National Medical Products Administration (NMPA) for clinical trials.

CNBG will conduct clinical trials on sequential Immunization of the new vaccine candidate, using a randomized, double-blind, cohort study to evaluate the safety and immunogenicity of an inactivated vaccine against Omicron variant in a population aged 18 years and older who have completed two or three doses of COVID-19 vaccination.